For some, it’s the flu.
For others, it may be an infection, a cold, a cough, or an infection.
And for others, they’re on medication to treat a viral infection or other symptoms of the flu, such as coughs and sore throat.
In the last week, a group of people in the UK has become familiar with a brand new treatment drug for the flu and are now struggling with the flu-like symptoms.
“It’s a real struggle.
I’ve been on medication for a few weeks,” said David, a 45-year-old father of four from Northampton.
He’s been taking the flu medication for five months, starting with the H1N1 vaccine.
David was diagnosed with a cold last week that made him sick, and he’s been on the flu treatment medication for seven days.
But it’s not all bad news.
David said the flu has been less of a problem this week, and has felt less of the symptoms.
He said the treatment drug, a synthetic version of the anti-viral drug, has helped him feel better, and his cough has gone down.
But he still feels uncomfortable and tired.
“I’ve been in hospital and I haven’t had any problems at all.
But I’m not happy with the way I’m feeling,” he said.
David is one of hundreds of people from across the country who have taken the H2N2 vaccine and have found that they have become more familiar with the treatment medication and its side effects, including mild flu symptoms such as cold sweats and sore throats.
They’ve also found that the treatment, known as methylene blue, is effective.
It has been the standard treatment for flu since the pandemic, but has recently been expanding to include the H3N2 influenza vaccine, which is given at home.
However, the H5N1 flu vaccine, known to be safer, has not yet been approved by the US Food and Drug Administration.
And the H4N2 flu vaccine has also not been approved.
The new H2O4 vaccine, available from the US Vaccine Alliance, is also not yet approved by FAS.
Experts warn that H2 vaccines are not yet ready for prime time and are still in the early stages of testing.
“We need to wait until the influenza vaccine is approved before we start to get ready for H2 and H4,” said Dr. Richard Sabin, an infectious diseases physician and director of the infectious diseases department at Mount Sinai Hospital in New York City.
Dr. David is one among many people who are on the lookout for the new vaccine.
He says he is in the process of trying it out, and is looking forward to it.
A new H1, or influenza, strain is expected to be released later this year.
Although many of the patients in the group of UK people on the treatment are now experiencing flu-related symptoms, David believes he’s on the right path.
“[I]t’s been a really long, hard journey,” he told The Globe and Mail.
“It has made me a little bit more confident that I’m on the correct path.”
David, who is currently taking a course to get a flu shot, says he wants to make sure he knows the benefits of the treatment before he takes it.